3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
13
Terminated
5
Active not recruiting
5
Withdrawn
1
Unknown
1
Suspended
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lymphoma, Large B-Cell, Diffuse
11
Lymphoma
11
Small Cell Lung Carcinoma
6
Lymphoma, Non-Hodgkin
5
Lymphoma, Follicular
5
Lung Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Carcinoma, Non-Small-Cell Lung
4
Burkitt Lymphoma
4
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large-Cell, Anaplastic
3
Hodgkin Disease
3
Waldenstrom Macroglobulinemia
2
Sarcoma
2
Recurrence
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, AIDS-Related
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Immunoblastic Lymphadenopathy
2
Dendritic Cell Sarcoma, Interdigitating
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thymoma
1
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Sezary Syndrome
1
Interventions
Cisplatin
9
pembrolizumab
7
Radiosurgery
6
Gemcitabine
6
Paclitaxel
5
Dexamethasone
5
Taxes
4
Carboplatin
4
trametinib
3
ibrutinib
3
Surveys and Questionnaires
3
Standard of Care
3
Radiotherapy
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Lenalidomide
3
Fluorouracil
3
Erlotinib Hydrochloride
3
Blood Specimen Collection
3
Ascorbic Acid
3
venetoclax
2
veliparib
2
tocilizumab
2
pazopanib
2
obinutuzumab
2
naquotinib
2
lenvatinib
2
fludarabine
2
enzalutamide
2
Vemurafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasms
×
Etoposide
×
Clear all
NCT02947113
2017-11-30
HYPOLAN
The Netherlands Cancer Institute
Phase 2
Withdrawn